KRAS is the most common biomarker associated with lung, colorectal, pancreatic plus other cancers. Identified 50 years ago, researchers have learned that different sub-types of KRAS respond to treatments differently.
We founded KRAS Kickers to actively monitor and share KRAS-related research developments, information and clinical trials within the community that will benefit the most, us. We are the patients that need the best outcomes to live our lives.
A biomarker is something measured by your doctor. This helps to identify the best treatment options for your cancer. KRAS targeted therapies are becoming options.
Watch Terri's interview with Dr. David Carbone to learn more:
Dr. David Carbone is a professor of internal medicine, director of the James Thoracic Center at The Ohio State University Comprehensive Cancer Center, and holds the Barbara J. Bonner Chair in Lung Research. His research interests have been focused on lung cancer, lung cancer genetics, cancer immunotherapy, and tumor-associated immunosuppression mechanisms.
Want to watch more videos with Dr. Carbone?
More Videos with Dr. David Carbone: